NASDAQ: TSHATaysha Gene Therapies Inc Stock
$2.54-0.11 (-4.15%)
Updated Jun 13, 2025
TSHA Price
$2.54
Fair Value Price
-$0.14
Market Cap
$545.24M
52 Week Low
$1.05
52 Week High
$4.07
P/E
-7.47x
P/B
9.9x
P/S
51.82x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.22M
Earnings
-$86.77M
Gross Margin
100%
Operating Margin
-1,199.81%
Profit Margin
-1,201.1%
Debt to Equity
1.51
Operating Cash Flow
-$83M
Beta
1.82
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TSHA Overview
Taysha Gene Therapies Incorporated is a gene therapy company developing and commercializing adeno-associated virus-based gene therapies to treat monogenic diseases of the central nervous system.Offerings include TSHA-120 for the treatment of giant axonal neuropathy, TSHA-102 for the treatment of Rett syndrome, TSHA-121 for the treatment of CLN1 disease, TSHA-118 for the treatment of CLN1 disease, TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha was incorporated in 2019 and is headquartered in Dallas, TX.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TSHA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TSHA
Ranked#78 of 464
Ranked#78 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important TSHA news, forecast changes, insider trades & much more!
TSHA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TSHA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TSHA ($2.54) is overvalued by 1,971.09% relative to our estimate of its Fair Value price of -$0.14 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TSHA ($2.54) is not significantly undervalued (1,971.09%) relative to our estimate of its Fair Value price of -$0.14 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TSHA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TSHA due diligence checks available for Premium users.
Valuation
TSHA fair value
Fair Value of TSHA stock based on Discounted Cash Flow (DCF)
Price
$2.54
Fair Value
-$0.14
Undervalued by
1,971.09%
TSHA ($2.54) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TSHA ($2.54) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TSHA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TSHA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.47x
Industry
-108.97x
Market
31.36x
TSHA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
9.9x
Industry
4.66x
TSHA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TSHA's financial health
Profit margin
Revenue
$2.3M
Net Income
-$21.5M
Profit Margin
-935.2%
TSHA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TSHA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$138.4M
Liabilities
$83.3M
Debt to equity
1.51
TSHA's short-term assets ($120.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TSHA's short-term assets ($120.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TSHA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$22.0M
Investing
-$371.0k
Financing
-$52.0k
TSHA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TSHA vs Biotech Stocks
Taysha Gene Therapies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.